Future Cardia™ Insertable Cardiac Monitor in Subjects With Paroxysmal Atrial Fibrillation (First-in-Human Study)

Atrial Fibrillation Clinical Trial

Official title:

Clinical Investigation of the Future Cardia™ Insertable Cardiac Monitor in Subjects With Paroxysmal Atrial Fibrillation Voice Of the Heart Trial (First-in-Human Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06167434
• Other study ID #: FC-2022-01
• Status: Recruiting
• Phase: N/A
• Start date: December 1, 2023
• Est. completion date: December 2024

Study information

• Verified date: January 2024
• Source: Future Cardia, Inc
• Contact: Jaeson Bang
• Phone: +1 727 470 3466
• Email: jaeb[@]futurecardia.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a first-in-human, prospective, multi-center, pre-market single-arm clinical trial to evaluate the Future Cardia™ ICM.

Description:

The objective of this first-in-human, prospective, multi-center, pre-market single-arm clinical investigation is to evaluate the safety and performance of the Future Cardia™ ICM by assessing the insertion procedure, sensing and detection performance and data monitoring transmission success, and device- or procedure-related complication rates over a 6-month follow-up period.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Adult patients (=18 years old and <75 years old)

2. Paroxysmal AF, defined as AF that terminates spontaneously or with intervention within 7 days of onset (ESC 2020 guidelines). In order to be included, patients must present

one of the following conditions:

1. paroxysmal AF patients that are candidates for AF ablation;

2. patients hospitalized for symptomatic AF, who failed to convert in the emergency

room (ER):

3. outpatients who require treatment with anti-arrhythmic drugs (AAD) (mostly propafenone or flecainide; more rarely sotalol or amiodaron are given for PAF).

3. Patient is willing and able to provide written informed consent.

4. Patient is willing and able to comply with the protocol, including follow-up visits and data transmissions.

Exclusion Criteria:

1. Patient who is scheduled to have MRI or is likely to require MR screening. The Future Cardia implant is not compatible with MRI.

2. Currently indicated for or implanted with a cardiovascular implantable electronic device (CIED) (e.g., ICM or ILR, pacemaker, ICD, CRT-D or CRT-P device) or hemodynamic monitoring system.

3. Compromised immune system or at high risk of developing an infection.

4. Active systemic infection or history of any infection within the last 30 days.

5. Subjects who are female must:

1. have a negative pregnancy test by ß-hCG blood test.

2. not breastfeeding

3. either be surgically sterile, postmenopausal (cessation of menses for at least 1 year), or if they have childbearing potential, agree to use a medically accepted, highly effective method of contraception during the entire duration of the study.

6. Subject is currently enrolled in another investigational study.

7. Any condition or abnormality (including clinical laboratory, physical examination, or vital sign abnormalities), current or past, that, in the opinion of the Investigator, would compromise the efficacy evaluation, safety of the patient, or would interfere with or complicate study procedures or assessments.

8. Any concomitant condition which, in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse, emotional/psychological diagnosis).

9. Obesity, Class 2 (BMI = 35-40) or Class 3 (BMI = 40).

10. Subject is unwilling or unable to comply with the study procedures.

11. Subject is legally incapacitated and unable to provide written informed consent.

Exclusion criteria for the study procedure:

12. Patient with abnormal thoracic anatomy or scar tissue at the implant site that may adversely impact the insertion procedure.

13. For patients currently taking warfarin at the time of insertion, most recent INR value (within 7 days) is less than 3.5 for an acceptable risk of bleeding.

Related Conditions & MeSH terms

• Arrhythmias, Cardiac
• Asystole
• Atrial Fibrillation
• Bradycardia
• Tachycardia
• Tachycardia, Ventricular
• Ventricular Tachycardia

Intervention

Device:
• Future Cardia™ Insertable Cardiac Monitoring (ICM) System
The Future Cardia™ ICM procedure will be performed as a stand-alone procedure for subcutaneous insertion.

Locations

Country	Name	City	State
Croatia	University Hospital of Split	Split

Sponsors (2)

Lead Sponsor	Collaborator
Future Cardia, Inc	Meditrial Europe Ltd.

Country where clinical trial is conducted

Croatia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Characterization of Insertion Procedure - Implantation: Insertion Success	Insertion Success. (Yes/No)	Day 0
Primary	Characterization of Insertion Procedure - Implantation: Incision Size	Incision Size in millimeters (mm).	Day 0
Primary	Characterization of Insertion Procedure - Implantation: Device Orientation	Device Orientation: Location between the suprasternal notch and the left nipple, (position A); or left parasternal region (position B) or left sub-mammary position can be used (position C).	Day 0
Primary	Characterization of Insertion Procedure - Implantation: Duration of Insertion Procedure.	Duration of Insertion Procedure in minutes (min).	Day 0
Primary	Characterization of Explant Procedure - Device removal: Removal Success	Removal Success (Yes/No)	up to 6 months
Primary	Characterization of Explant Procedure - Device removal: Incision Size	Incision Size in millimeters (mm)	Up to 6 months
Primary	Characterization of Explant Procedure - Device removal: Duration of explant procedure	Duration of explant procedure in minutes (min).	Up to 6 months
Primary	Device and Procedural Safety over a period of 180 days	Number of Serious Adverse Events (SAE) related to the Device or insertion procedure.; Number of Participants with Device-related or Procedure-related Serious Adverse Event that require additional invasive intervention (including need to for device removal, device replacement, surgical repositioning of the device, or another surgery related to the device or primary insertion procedure).	6 months
Primary	Success of Wireless Transmissions over a period of 180 days	Assess the percentage of successful wireless transmissions from the system throughout the study duration (transmission successful, the transmission failed or transmission re-try).	6 months
Secondary	Evaluation of the sensing quality of Future Cardia™ ICM, through assessment of the ECG signal by two independent electrophysiologists.	ECG signal Assessment.	6 months
Secondary	Comparison of the Future Cardia™ ECG tracing and detection of arrhythmias with 7-day ECG recorder tracings or 24-hr Holter recording (optional, when available).	Comparison of the Future Cardia™ ECG tracing and detection of arrhythmias with 7-day ECG recorder tracings or 24-hr Holter recording.	6 months
Secondary	Usability: survey of the implanting physicians regarding the ease of implantation and use of the system for monitoring during follow-up.	Usability Survey	6 months
Secondary	Number of Serious Adverse Events (SAE) related to the Device or study procedure in patients who elect to continue monitoring using the ICM device after the 6-month study follow-up.	Long-term safety in Post study follow-up (> 6 months up to 2 years).	2 Years

External Links

•   Future Cardia Inc.Website
•   Meditrial Europe Ltd.CRO